Cancer Epidemiology
Volume 34, Issue 3 , Pages 244-256 , June 2010

Monitoring the decreasing trend of testicular cancer mortality in Spain during 2005–2019 through a Bayesian approach

  • Ramon Clèries

      Affiliations

    • Catalan Plan for Oncology, Institut Català d’Oncologia – IDIBELL, Gran Via s/n, km 2,7 L’Hospitalet de Llobregat, Barcelona 08907, Spain
    • Dept. of Clinical Sciences, Universitat de Barcelona, Barcelona, Spain
    • Corresponding Author InformationCorresponding author at: Catalan Plan for Oncology, Institut Català d’Oncologia – IDIBELL, Gran Via s/n, km 2,7 L’Hospitalet de Llobregat, Barcelona 08907, Spain. Tel.: +34 93 260 78 12; fax: +34 93 260 77 87.
    • ,
  • José Miguel Martínez

      Affiliations

    • Centro de Investigación en Salud Laboral (CiSAL), Universitat Pompeu Fabra, Barcelona, Spain
    • Grup de Recerca de Desigualtats en Salut (GREDS/EMCONET), Universitat Pompeu Fabra, Barcelona, Spain
    • ,
  • Josep Maria Escribà

      Affiliations

    • Catalan Plan for Oncology, Institut Català d’Oncologia – IDIBELL, Gran Via s/n, km 2,7 L’Hospitalet de Llobregat, Barcelona 08907, Spain
    • ,
  • Laura Esteban

      Affiliations

    • Catalan Plan for Oncology, Institut Català d’Oncologia – IDIBELL, Gran Via s/n, km 2,7 L’Hospitalet de Llobregat, Barcelona 08907, Spain
    • ,
  • Laura Pareja

      Affiliations

    • Catalan Plan for Oncology, Institut Català d’Oncologia – IDIBELL, Gran Via s/n, km 2,7 L’Hospitalet de Llobregat, Barcelona 08907, Spain
    • ,
  • Josep Maria Borràs

      Affiliations

    • Catalan Plan for Oncology, Institut Català d’Oncologia – IDIBELL, Gran Via s/n, km 2,7 L’Hospitalet de Llobregat, Barcelona 08907, Spain
    • Dept. of Clinical Sciences, Universitat de Barcelona, Barcelona, Spain
    • ,
  • Josepa Ribes

      Affiliations

    • Catalan Plan for Oncology, Institut Català d’Oncologia – IDIBELL, Gran Via s/n, km 2,7 L’Hospitalet de Llobregat, Barcelona 08907, Spain
    • Dept. of Clinical Sciences, Universitat de Barcelona, Barcelona, Spain

,Accepted 4 March 2010.

References 

  1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18(3):581–592
  2. Bray F, Richiardi L, Ekbom A, Pukkala E, Cuninkova M, Moller H. Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. Int J Cancer. 2006;118(12):3099–3111
  3. Huyghe E, Plante P, Thonneau PF. Testicular cancer variations in time and space in Europe. Eur Urol. 2007;51(3):621–628
  4. Richiardi L, Akre O, Lambe M, Granath F, Montgomery SM, Ekbom A. Birth order, sib ship size, and risk for germ-cell testicular cancer. Epidemiology. 2004;15(3):323–329
  5. Hsieh CC, Lambe M, Trichopoulos D, Ekbom A, Akre O, Adami HO. Early life exposure to oestrogen and testicular cancer risk: evidence against an aetiological hypothesis. Br J Cancer. 2002;86(8):1363–1364
  6. Moller H, Jorgensen N, Forman D. Trends in incidence of testicular cancer in boys and adolescent men. Int J Cancer. 1995;61(6):761–764
  7. Akre O, Lipworth L, Cnattingius S, Sparen P, Ekbom A. Risk factor patterns for cryptorchidism and hypospadias. Epidemiology. 1999;10(4):364–369
  8. Pettersson A, Kaijser M, Richiardi L, Askling J, Ekbom A, Akre O. Women smoking and testicular cancer: one epidemic causing another?. Int J Cancer. 2004;109(6):941–944
  9. Weir HK, Marrett LD, Kreiger N, Darlington GA, Sugar L. Pre-natal and peri-natal exposures and risk of testicular germ-cell cancer. Int J Cancer. 2000;87(3):438–443
  10. Alfonso JL, Cortes C, Gimenez F, Cortina P. Cancer of the testis: risk factors and evolution of mortality in Spain (1951–1983). Arch Esp Urol. 1989;42(8):755–760
  11. Fernandez QG, Monge JV, Lopez-Abente OG, Vincente Perez JA. Transitory trends in the mortality of testicular cancer in Spain 1953–1977. Actas Urol Esp. 1988;12(4):340–346
  12. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the. Eur J Cancer. 1990;2008
  13. Spiegelhalter DJ, Thomas A, Best N, Lunn D . WinBUGS User Manual, Version 1.4. Cambridge, England: MRC Biostatistics Unit; 2002;
  14. R Development Core Team. R: A language and environment for statistical computing, R Foundation for Statistical Computing, Vienna, Austria, 2006. ISBN 3-900051-07-0. http://www.R-project.org 2006; Available at: URL: http://www.R-project.org.
  15. Sturtz S, Ligges U, Gelman A. R2WinBUGS: a package for running WinBUGS from R. J Stat Soft. 2005;12(3):1–16
  16. World Health Organization . International classification of diseases, Tenth Revision (ICD-10). Geneva: WHO; 1992;
  17. Clayton D, Schifflers E. Models for temporal variation in cancer rates. II. Age–period–cohort models. Stat Med. 1987;6(4):469–481
  18. Bashir SA, Estève J. Projecting cancer incidence and mortality using Bayesian age–period. Cohort models. J Epidemiol Biostat. 2001;6:287–296
  19. Knorr-Held L, Rainer E. Projections of lung cancer mortality in West Germany: a case study in Bayesian prediction. Biostatistics. 2001;2(1):109–129
  20. Cleries R, Ribes J, Esteban L, Martinez JM, Borras JM. Time trends of breast cancer mortality in Spain during the period 1977–2001 and Bayesian approach for projections during 2002–2016. Ann Oncol. 2006;17(12):1783–1791
  21. Gelman A. Prior distributions for variance parameters in hierarchical models. Bayesian Anal. 2005;1:1–19
  22. Spiegelhalter DJ, Best NG, Carlin BP, van der Linde AJ, Bayesian . Measures of model complexity and fit (with discussion). J Roy Stat Soc Ser B. 2002;64(3):583–639
  23. Holford TR. The estimation of age, period and cohort effects for vital rates. Biometrics. 1983;39:311–324
  24. Holford TR. Understanding the effects of age, period, and cohort on incidence and mortality rates. Annu Rev Publ Health. 1991;12:425–457
  25. Holford TR. An alternative approach to statistical age–period–cohort analysis. J Chronic Dis. 1985;38(10):831–840
  26. Holford TR. Analysing the temporal effects of age, period and cohort. Stat Methods Med Res. 1992;1(3):317–337
  27. Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977;87(3):293–298
  28. Becker N, Boyle P. Decline in mortality from testicular cancer in West Germany after reunification. Lancet. 1997;350(9079):744
  29. Thornhill JA, Conroy RM, Kelly DG, Walsh A, Fennelly JJ, Fitzpatrick JM. Recent trends in mortality due to testicular cancer in Ireland: a comparison with England and Wales. J Epidemiol Community Health. 1986;40(3):218–222
  30. Brown LM, Pottern LM, Hoover RN, Devesa SS, Aselton P, Flannery JT. Testicular cancer in the United States: trends in incidence and mortality. Int J Epidemiol. 1986;15(2):164–170
  31. Osterlind A. Diverging trends in incidence and mortality of testicular cancer in Denmark, 1943–1982. Br J Cancer. 1986;53(4):501–505
  32. Richiardi L, Bellocco R, Adami HO, Torrang A, Barlow L, Hakulinen T, et al. Testicular cancer incidence in eight northern European countries: secular and recent trends. Cancer Epidemiol Biomarkers Prev. 2004;13:2157–2166
  33. Peckham MJ, McElwain TJ, Barrett A, Hendry WF. Combined management of malignant teratoma of the testis. Lancet. 1979;2(8137):267–270
  34. Oliver RT, Ong J, Blandy JP, Altman DG. Testis conservation studies in germ cell cancer justified by improved primary chemotherapy response and reduced delay, 1978–1994. Br J Urol. 1996;78(1):119–124
  35. Cambil J. Effectiveness of testicular self-examination and screening for an early detection of testicular cancer. Index Enferm. 2005;14:48–49
  36. Webb V, Holmes A. Urological cancers: do early detection strategies exist?. BJU Int. 2000;86(9):996–1000
  37. Sant M, Aareleid T, Artioli ME, Berrino F, Coebergh JW, Colonna M, et al. Ten-year survival and risk of relapse for testicular cancer: a EUROCARE high resolution study. Eur J Cancer. 2007;43(3):585–592
  38. Einhorn LH. Curing metastatic testicular cancer. Proc Natl Acad Sci USA. 2002;99(7):4592–4595
  39. Sant M, Aareleid T, Berrino F, Lasota MB, Carli PM, Faivre J, et al. EUROCARE-3: survival of cancer patients diagnosed 1990–94—results and commentary. Ann Oncol. 2003;14(Suppl. 5):v61–v118
  40. Berrino F, De Angelis R, Sant M, Rosso S, Lasota MB, Coebergh JW, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study. Lancet Oncol. 2007;8(9):773–783
  41. Berrino F, Capocaccia R, Estève J, Gatta G, Hakulinen T, Micheli A, et al. Survival of cancer patients in Europe: the EUROCARE-2 Study. IARC Scientific Press; 1999;
  42. Eurostat. Non-national populations in the EU Member States. Eurostat Population and social conditions 2006; Issue number 8; Available at: URL: http://epp.eurostat.ec.europa.eu/cache/ITY_OFFPUB/KS-NK-06-008/EN/KS-NK-06-008-EN.PDF, Accessed on June 15, 2006.
  43. Bray F, Moller B. Predicting the future burden of cancer. Nat Rev Cancer. 2006;6(1):63–74
  44. Richie JP. Impact of diagnostic delay in testis cancer: results of a large population-based study Huyghe E, Muller A, Mieusset R, Bujan L, Bachaud JM, Chevreau C, Plante P, Thonneau P, Human Fertility Research Group, Paule de Viguier Hospital, Toulouse University III, France; Urology and Andrology Department, Paule de Viguier Hospital, Toulouse, France. Urol Oncol. 2008;26(2):220–221

PII: S1877-7821(10)00036-6

doi: 10.1016/j.canep.2010.03.003

Cancer Epidemiology
Volume 34, Issue 3 , Pages 244-256 , June 2010

Article Tools

* Image Usage & Resolution